tradingkey.logo
tradingkey.logo
Suchen

Renovaro Inc

RENB
Zur Watchlist hinzufügen
1.420USD
0.0000.00%
Handelsschluss 06/30, 16:00ETKurse um 15 Minuten verzögert
14.83MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Renovaro Inc Unternehmen

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Renovaro Inc Informationen

BörsenkürzelRENB
Name des UnternehmensLunai Bioworks Inc
IPO-datumNov 18, 2014
CEOWeinstein (David)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse2080 Century Park East, Suite 906
StadtLOS ANGELES
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl90067
Telefon14539179840
Website
BörsenkürzelRENB
IPO-datumNov 18, 2014
CEOWeinstein (David)

Führungskräfte von Renovaro Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Renovaro Inc?

Die fünf größten Anteilseigner von Renovaro Inc sind: Mr. Douglas W. Calder

Wie viele Institutionen halten Anteile an Renovaro Inc (RENB)?

Mit Stand vom 2026Q1 halten 139 Institutionen Anteile an Renovaro Inc, mit einem Gesamtmarktwert von etwa 1.10M, was 3.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -513101.00 gestiegen.